| Literature DB >> 31839777 |
Zorica Sojević Timotijević1, Goran Trajković2, Janko Jankovic3, Milijana Relić1, Dragica Đorić1, Danica Vukićević4, Goran Relić5, Dragiša Rašić6, Milan Filipović7, Slavenka Janković8.
Abstract
INTRODUCTION: Palmoplantar psoriasis (PPP) is a variant of psoriasis that affects the palms and/or soles. Although PPP is a disabling and therapeutically challenging condition, its epidemiology is poorly defined. AIM: To assess the prevalence of PPP locations (palms, soles or both), and to analyse epidemiological and clinical characteristics of the disease.Entities:
Keywords: epidemiology; meta-analysis; palmoplantar psoriasis; prevalence; systematic review
Year: 2019 PMID: 31839777 PMCID: PMC6906961 DOI: 10.5114/ada.2019.89508
Source DB: PubMed Journal: Postepy Dermatol Alergol ISSN: 1642-395X Impact factor: 1.837
Figure 1Flow diagram of study identification, inclusion and exclusion criteria
Description of studies included in the systematic review and meta-analysis of palmoplantar psoriasis
| First author, year | Country | Type of study | Study dates | Study population | Clinical type | Palms/soles involved, | Rest body involved | Disease measures |
|---|---|---|---|---|---|---|---|---|
| Adişen, 2009 | Turkey | Retrospective cohort study | 2003–2007 | 114 patients | Plaque or hyperkeratotic | P or S: 22 (19.2) | NA | NA |
| Al-Mutairi, 2014 | Kuwait | Case-series | January 2011 to January 2013 | 103 patients | Plaque | P: 14 (13.6) | Yes | NA |
| Angelovska, 2014 | Germany | Case-series | 2007–2012 | 6 patients | Hyperkeratotic | P: 5 (83.3) | Yes | NA |
| Bissonnette, 2011 | Canada | Randomized double blind trial | February 2007 to July 2008 | 24 patients | Plaque | P: 2 (8.3) | Yes | PPSA ≥ 10%; m–PPPASI ≥ 8; PGA; DLQI |
| Brunasso, 2010 | Austria | Case-series | January 2005 to December 2009 | 19 patients | Pustular | P: 6 (31.6) | Yes | PGA score ≤ 2 outside the PPSA |
| Brunasso, 2013 | Italy and Austria | Retrospective case-series | January 2005 to January 2010 | 90 patients, mean age: 57.7 y; range: 11–82 y | Plaque | P: 21 (23.3) | Yes | BSA outside the PPSA ≤ 5%; PGA score ≤ 2 outside the PPSA |
| Coleman, 1989 | United States | Retrospective cohort study | April 1986 to November 1987 | 11 patients | Plaque | P: 3 (27.2 ) | NA | Four point scale score |
| Farley, | United States | Retrospective cohort study | August 2006 to March 2008 | 150 patients | Hyperkeratotic Pustular Hyperkeratotic/pustular | P: 21 (14.0) | Yes | PPSA ≥ 50%; BSA outside the PPSA; PPQoLI |
| Haseena, 2017 | India | Open trial | October 2009 to September 2010 | 28 patients, mean age: 42.2 y; range: 14–68 y | Plaque or hyperkeratotic | P: 8 (28.6) | Yes | PPSA > 30%; BSA outside the PPSA ≤ 5%; ESIF score |
| Hofer, 2006 | Austria | Randomized trial | NA | 8 patients | Pustular Hyperkeratotic | P: 2 (25.0) | NA | SI (erythema, infiltration, scaling and vesicles) |
| Janagond, 2013 | India | Randomized trial | January 2011 to February 2012 | 100 patients Age range: 17–53 y | Plaque | P: 3 (3.0) | Yes | PPSA ≥ 50%; m-PPPASI |
| Khandpur, 2011 | India | Case-series | 2006–2008 | 154 patients, age range: 21–50 y (for 67% of patients) | NA | P: 24 (15.6) | Yes | NA |
| Kumar, 1997 | India | Randomized trial | NA | 28 patients | Plaque | P: 4 (14.3) | Yes | PPSA ≥ 30%; BSA outside the PPSA ≤ 5%; ESI score |
| Kumar, 2002 | India | Retrospective cohort study | 1993–2000 | 532 patients | Plaque/hyperkeratotic | P: 43 (8.1) | Yes | BSA outside the PPSA ≤ 30% |
| Kumar, 2004 | India | Open trial | NA | 14 patients | Plaque | P: 2 (14.3) | NA | PPSA ≥ 30%; ESIF score |
| Lawrence, 1984 | England | Randomized double blind trial | NA | 20 patients | Hyperkeratotic Pustular | P: 0 (0) | Yes | NA |
| Lior, 2010 | Israel | Open trial | NA | 7 patients | Plaque | P: 3 (42.9) | Yes | NA |
| Lozinski, 2016 | Israel | Retrospective cohort study | 2010–2012 | 248 patients | Plaque | P: 23 (9.3) | Yes | NA |
| Nisticò, 2006 | Italy | Open trial | NA | 54 patients | NA | P: 27 (50.0) | Yes | BSA outside the PPSA ≤ 30%; PASI |
| Ravi Kumar, 1999 | India | Case-series follow-up | NA | 15 patients | Plaque | P: 1 (6.7) | Yes | PPSA > 30%; BSA outside the PPSA ≤ 5%; ESIF score |
| Redon, 2010 | France | Case-series | November 2001 to April 2008 | 92 patients | Plaque/pustular | P: 43 (46.7) | NA | NA |
| Tanaka, 2000 | Japan | Case-series | NA | 9 patients | Pustular | P: 0 (0) | NA | PASI |
| Venkatesan, 2015 | India | Cross-sectional hospital based study | January to June 2014 | 236 patients | Plaque | P: 66 (28.0) | Yes | NA |
| Wilkinson, 1979 | Germany | Case-series | NA | 21 patients | Plaque or hyperkeratotic Pustular | P: 7 (33.3) | NA | NA |
Not included in meta-analysis, †for all psoriasis patients, PP – palmoplantar psoriasis, P – palms, S – soles, PS – both palms and soles, NA – not available, y – year, BSA – body surface area, PPSA – palmoplantar surface area, PGA – physician’s global assessment, m-PPPASI – modified palmoplantar (pustular) psoriasis area and severity index, DLQI – dermatology life quality index, PPQoLI – palmar-plantar quality of life index, PASI – psoriasis area and severity index, SI – severity index, ESI – erythema, scaling, induration, ESIF – erythema, scaling, induration, fissuring.
Figure 2Forest plot depicting proportions with their confidence intervals from the studies comparing involvement of affected sites in patients with palmoplantar psoriasis